Skip to content
Review Open access

Endothelin antagonism: a new era for resistant hypertension

Jun 2026 · Clinical Kidney Journal · Vol 19, pp. i61 - i70 · 0 citations · 82 references
Medicine

TL;DR

In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria, and may provide benefits beyond blood pressure reduction.

Abstract

ABSTRACT Hypertension is a major global health burden and a leading contributor to cardiovascular disease and chronic kidney disease (CKD). Despite the availability of multiple antihypertensive therapies, blood pressure control remains suboptimal, and a significant proportion of patients develop resistant hypertension, defined as uncontrolled blood pressure despite treatment with three or more agents including a diuretic. These individuals are at particularly high risk of adverse cardiovascular and renal outcomes, highlighting an unmet need for novel therapeutic strategies. Endothelin-1, the most potent endogenous vasoconstrictor, plays a key role in the regulation of vascular tone, sodium balance and renal function. Dysregulation of the endothelin system has been implicated in the pathophysiology of resistant hypertension through its interactions with the renin-angiotensin-aldosterone system, sympathetic nervous system activation and endothelial dysfunction. Early studies of endothelin receptor antagonists in hypertension were limited by adverse effects, particularly fluid retention. However, the development of newer agents has renewed interest in this pathway. In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria. Endothelin antagonism represents a promising therapeutic approach in resistant hypertension, particularly in patients with CKD, and may provide benefits beyond blood pressure reduction.

Read PDF

Similar papers

Review Open access Nov 2026

New Drugs in the Treatment of Uncontrolled or Resistant Hypertension

Arterial hypertension remains one of the leading modifiable risk factors for cardiovascular and renal morbidity and mortality worldwide, while resistant hypertension continues to represent a major therapeutic challenge despite the widespread use of conventional antihypertensive agents. Recent advances in the understand...

M. Miedziaszczyk, Krzysztof Chrzanowski, Mateusz Konieczny et al. · 0 citations
Review Open access Oct 2026

Efficacy and mechanistic insights of dapagliflozin in hypertension management.

The available evidence supports dapagliflozin as a cardiorenal therapeutic agent that may provide additional BP-lowering benefits in patients with hypertension and concomitant T2D, CKD, or HF, rather than as a substitute for conventional antihypertensive therapy.

Zhong-Bo Chen, Chun-Bin Wang, Han-Mei Zhang et al. · 0 citations
Review Open access Nov 2026

Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances

Diabetic kidney disease (DKD) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a leading global cause of end-stage kidney disease (ESKD). Current first-line regimens, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors, only part...

Li Ma, Wen-Hua Liu, Xiao-Tong Wang et al. · 0 citations
Review Open access Nov 2026

Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target. Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral a...

Y. Rachmawan, Witri Pratiwi, Bagus Andi Pramono et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.